Androgen receptor as a therapeutic target for androgen independent prostate cancer

Am J Ther. Mar-Apr 2006;13(2):166-70. doi: 10.1097/00045391-200603000-00013.

Abstract

Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.

Publication types

  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Aged
  • Androgens / physiology*
  • Humans
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Receptors, Androgen / drug effects
  • Receptors, Androgen / physiology*

Substances

  • Androgens
  • Receptors, Androgen